哺乳动物雷帕霉素靶蛋白调控多囊蛋白-2缺陷型小鼠血管内皮生长因子依赖性肝囊肿生长。
Mammalian target of rapamycin regulates vascular endothelial growth factor-dependent liver cyst growth in polycystin-2-defective mice.
机构信息
Section of Digestive Diseases, Department of Internal Medicine, Yale University, New Haven, CT 06520, USA.
出版信息
Hepatology. 2010 May;51(5):1778-88. doi: 10.1002/hep.23511.
UNLABELLED
Polycystic liver disease may complicate autosomal dominant polycystic kidney disease (ADPKD), a disease caused by mutations in polycystins, which are proteins that regulate signaling, morphogenesis, and differentiation in epithelial cells. The cystic biliary epithelium [liver cystic epithelium (LCE)] secretes vascular endothelial growth factor (VEGF), which promotes liver cyst growth via autocrine and paracrine mechanisms. The expression of insulin-like growth factor 1 (IGF1), insulin-like growth factor 1 receptor (IGF1R), and phosphorylated mammalian target of rapamycin (p-mTOR) and the protein kinase A (PKA)-dependent phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2) are also up-regulated in LCE. We have hypothesized that mammalian target of rapamycin (mTOR) represents a common pathway for the regulation of hypoxia-inducible factor 1 alpha (HIF1alpha)-dependent VEGF secretion by IGF1 and ERK1/2. Conditional polycystin-2-knockout (Pkd2KO) mice were used for in vivo studies and to isolate cystic cholangiocytes [liver cystic epithelial cells (LCECs)]. The expression of p-mTOR, VEGF, cleaved caspase 3 (CC3), proliferating cell nuclear antigen (PCNA), IGF1, IGF1R, phosphorylated extracellular signal-regulated kinase, p-P70S6K, HIF1alpha, and VEGF in LCE, LCECs, and wild-type cholangiocytes was studied with immunohistochemistry, western blotting, or enzyme-linked immunosorbent assays. The cystic area was measured by computer-assisted morphometry of pancytokeratin-stained sections. Cell proliferation in vitro was studied with 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium and bromodeoxyuridine assays. The treatment of Pkd2KO mice with the mTOR inhibitor rapamycin significantly reduced the liver cyst area, liver/body weight ratio, pericystic microvascular density, and PCNA expression while increasing expression of CC3. Rapamycin inhibited IGF1-stimulated HIF1alpha accumulation and VEGF secretion in LCECs. IGF1-stimulated LCEC proliferation was inhibited by rapamycin and SU5416 (a vascular endothelial growth factor receptor 2 inhibitor). Phosphorylation of the mTOR-dependent kinase P70S6K was significantly reduced by PKA inhibitor 14-22 amide and by the mitogen signal-regulated kinase inhibitor U1026.
CONCLUSION
These data demonstrate that PKA-dependent up-regulation of mTOR has a central role in the proliferative, antiapoptotic, and pro-angiogenic effects of IGF1 and VEGF in polycystin-2-defective mice. This study also highlights a mechanistic link between PKA, ERK, mTOR, and HIF1alpha-mediated VEGF secretion and provides a proof of concept for the potential use of mTOR inhibitors in ADPKD and conditions with aberrant cholangiocyte proliferation.
目的
多囊性肝病可能并发常染色体显性多囊肾病(ADPKD),后者是由多囊蛋白突变引起的疾病,多囊蛋白是调节信号转导、形态发生和上皮细胞分化的蛋白质。囊性胆管上皮细胞[肝囊性上皮细胞(LCE)]分泌血管内皮生长因子(VEGF),通过自分泌和旁分泌机制促进肝囊肿生长。胰岛素样生长因子 1(IGF1)、胰岛素样生长因子 1 受体(IGF1R)和磷酸化哺乳动物雷帕霉素靶蛋白(p-mTOR)的表达以及蛋白激酶 A(PKA)依赖性细胞外信号调节激酶 1/2(ERK1/2)的磷酸化在 LCE 中也被上调。我们假设雷帕霉素(mTOR)靶蛋白代表调节 IGF1 和 ERK1/2 依赖性缺氧诱导因子 1 阿尔法(HIF1alpha)依赖性 VEGF 分泌的共同途径。使用条件性多囊蛋白-2 敲除(Pkd2KO)小鼠进行体内研究,并分离囊性胆管细胞[肝囊性上皮细胞(LCEC)]。通过免疫组织化学、western blot 或酶联免疫吸附试验研究 LCE、LCEC 和野生型胆管细胞中 p-mTOR、VEGF、cleaved caspase 3(CC3)、增殖细胞核抗原(PCNA)、IGF1、IGF1R、磷酸化细胞外信号调节激酶、p-P70S6K、HIF1alpha 和 VEGF 的表达。使用细胞角蛋白染色的组织切片通过计算机辅助形态计量法测量囊肿面积。体外细胞增殖通过 3-(4,5-二甲基噻唑-2-基)-5-(3-羧基甲氧基苯基)-2-(4-磺基苯基)-2H-四唑和溴脱氧尿苷测定法进行研究。用 mTOR 抑制剂雷帕霉素治疗 Pkd2KO 小鼠可显著减少肝囊肿面积、肝/体重比、囊周微血管密度和 PCNA 表达,同时增加 CC3 表达。雷帕霉素抑制 IGF1 刺激的 LCEC 中 HIF1alpha 积累和 VEGF 分泌。雷帕霉素和 SU5416(血管内皮生长因子受体 2 抑制剂)抑制 IGF1 刺激的 LCEC 增殖。PKA 抑制剂 14-22 酰胺和丝裂原信号调节激酶抑制剂 U1026 显著降低 mTOR 依赖性激酶 P70S6K 的磷酸化。
结论
这些数据表明,PKA 依赖性 mTOR 上调在多囊蛋白-2 缺陷小鼠中 IGF1 和 VEGF 的增殖、抗凋亡和促血管生成作用中起核心作用。本研究还强调了 PKA、ERK、mTOR 和 HIF1alpha 介导的 VEGF 分泌之间的机制联系,并为 mTOR 抑制剂在 ADPKD 和异常胆管细胞增殖中的潜在用途提供了概念验证。